JP2019501226A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501226A5 JP2019501226A5 JP2018555315A JP2018555315A JP2019501226A5 JP 2019501226 A5 JP2019501226 A5 JP 2019501226A5 JP 2018555315 A JP2018555315 A JP 2018555315A JP 2018555315 A JP2018555315 A JP 2018555315A JP 2019501226 A5 JP2019501226 A5 JP 2019501226A5
- Authority
- JP
- Japan
- Prior art keywords
- manganese
- active agent
- individual
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013543 active substance Substances 0.000 claims 29
- 239000003814 drug Substances 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 19
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 15
- 229910052748 manganese Inorganic materials 0.000 claims 15
- 239000011572 manganese Substances 0.000 claims 15
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 14
- 229960004308 acetylcysteine Drugs 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- SQKUFYLUXROIFM-UHFFFAOYSA-N 2-[2-[carboxymethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]ethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]acetic acid Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN(CCN(CC(O)=O)CC=2C(=C(C)N=CC=2COP(O)(O)=O)O)CC(O)=O)=C1O SQKUFYLUXROIFM-UHFFFAOYSA-N 0.000 claims 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 10
- 239000012190 activator Substances 0.000 claims 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 6
- -1 DPDP compound Chemical class 0.000 claims 6
- 229910052791 calcium Inorganic materials 0.000 claims 6
- 239000011575 calcium Substances 0.000 claims 6
- UMRUNOIJZLCTGG-UHFFFAOYSA-N calcium;manganese Chemical compound [Ca+2].[Mn].[Mn].[Mn].[Mn] UMRUNOIJZLCTGG-UHFFFAOYSA-N 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000004696 coordination complex Chemical class 0.000 claims 6
- 208000007788 Acute Liver Failure Diseases 0.000 claims 5
- 206010000804 Acute hepatic failure Diseases 0.000 claims 5
- 108010024636 Glutathione Proteins 0.000 claims 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 5
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 5
- 231100000836 acute liver failure Toxicity 0.000 claims 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 5
- 235000018417 cysteine Nutrition 0.000 claims 5
- 229960003180 glutathione Drugs 0.000 claims 5
- HGZODADXHUPMQO-UHFFFAOYSA-N 4-[(2-aminoethylamino)methyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound Cc1ncc(CO)c(CNCCN)c1O HGZODADXHUPMQO-UHFFFAOYSA-N 0.000 claims 4
- JFVHALAXWREODT-UHFFFAOYSA-N C(C=1C(CO)=CN=C(C)C1O)NCCN.[Mn] Chemical compound C(C=1C(CO)=CN=C(C)C1O)NCCN.[Mn] JFVHALAXWREODT-UHFFFAOYSA-N 0.000 claims 4
- 229960005489 paracetamol Drugs 0.000 claims 4
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims 4
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims 4
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims 4
- 229960001327 pyridoxal phosphate Drugs 0.000 claims 4
- 239000013589 supplement Substances 0.000 claims 4
- 150000001408 amides Chemical class 0.000 claims 3
- UJCHIZDEQZMODR-BYPYZUCNSA-N (2r)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 claims 2
- 206010019851 Hepatotoxicity Diseases 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 231100000304 hepatotoxicity Toxicity 0.000 claims 2
- 230000007686 hepatotoxicity Effects 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- QAOJLUYEMFXJGX-UHFFFAOYSA-D tetracalcium [4-[[carboxymethyl-[2-[carboxymethyl-[[3-hydroxy-5-[[hydroxy(oxido)phosphoryl]oxymethyl]-2-methylpyridin-4-yl]methyl]amino]ethyl]amino]methyl]-5-hydroxy-6-methylpyridin-3-yl]methyl hydrogen phosphate manganese(2+) Chemical compound [Ca++].[Ca++].[Ca++].[Ca++].[Mn++].Cc1ncc(COP(O)([O-])=O)c(CN(CCN(CC(O)=O)Cc2c(COP(O)([O-])=O)cnc(C)c2O)CC(O)=O)c1O.Cc1ncc(COP(O)([O-])=O)c(CN(CCN(CC(O)=O)Cc2c(COP(O)([O-])=O)cnc(C)c2O)CC(O)=O)c1O.Cc1ncc(COP(O)([O-])=O)c(CN(CCN(CC(O)=O)Cc2c(COP(O)([O-])=O)cnc(C)c2O)CC(O)=O)c1O.Cc1ncc(COP(O)([O-])=O)c(CN(CCN(CC(O)=O)Cc2c(COP(O)([O-])=O)cnc(C)c2O)CC(O)=O)c1O.Cc1ncc(COP(O)([O-])=O)c(CN(CCN(CC(O)=O)Cc2c(COP(O)([O-])=O)cnc(C)c2O)CC(O)=O)c1O QAOJLUYEMFXJGX-UHFFFAOYSA-D 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021197319A JP7374163B2 (ja) | 2016-01-11 | 2021-12-03 | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277232P | 2016-01-11 | 2016-01-11 | |
| US62/277,232 | 2016-01-11 | ||
| US201662361605P | 2016-07-13 | 2016-07-13 | |
| US62/361,605 | 2016-07-13 | ||
| PCT/IB2017/050115 WO2017122120A1 (en) | 2016-01-11 | 2017-01-10 | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021197319A Division JP7374163B2 (ja) | 2016-01-11 | 2021-12-03 | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501226A JP2019501226A (ja) | 2019-01-17 |
| JP2019501226A5 true JP2019501226A5 (https=) | 2020-02-20 |
| JP7311267B2 JP7311267B2 (ja) | 2023-07-19 |
Family
ID=57909814
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555315A Active JP7311267B2 (ja) | 2016-01-11 | 2017-01-10 | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
| JP2021197319A Active JP7374163B2 (ja) | 2016-01-11 | 2021-12-03 | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021197319A Active JP7374163B2 (ja) | 2016-01-11 | 2021-12-03 | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11260060B2 (https=) |
| EP (2) | EP3842040B1 (https=) |
| JP (2) | JP7311267B2 (https=) |
| CN (1) | CN108601757A (https=) |
| AU (1) | AU2017208123B2 (https=) |
| CA (1) | CA3010915C (https=) |
| RU (1) | RU2018128793A (https=) |
| WO (1) | WO2017122120A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2964480A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| EP3842040B1 (en) * | 2016-01-11 | 2022-03-09 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| JP2020532515A (ja) | 2017-08-30 | 2020-11-12 | ペンデュラム セラピューティクス， インコーポレイテッド | マイクロバイオーム関連障害の処置のための方法および組成物 |
| RU2693677C1 (ru) * | 2018-10-15 | 2019-07-03 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ гемокоррекции при лечении печеночной недостаточности |
| CA3140096A1 (en) * | 2019-05-21 | 2020-11-26 | Pendulum Therapeutics, Inc. | Methods and compositions for treating liver disorders |
| WO2022269026A1 (en) | 2021-06-25 | 2022-12-29 | Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. | Treating acetaminophen overdose |
| WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566401B2 (en) | 2001-03-30 | 2003-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
| FR2823977B1 (fr) | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
| WO2005017094A2 (en) * | 2003-08-19 | 2005-02-24 | Bioadvantex Pharma Inc. | N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency |
| US20090234011A1 (en) | 2005-04-21 | 2009-09-17 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
| JP2010507572A (ja) * | 2006-10-23 | 2010-03-11 | ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア | 併用療法 |
| US20080139654A1 (en) * | 2006-12-09 | 2008-06-12 | Eric Mott Soderling | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity |
| CN105688215A (zh) * | 2009-07-06 | 2016-06-22 | 普莱制药公司 | 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法 |
| CN107353313B (zh) * | 2012-01-05 | 2019-04-09 | 普莱制药公司 | 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法 |
| US20140178358A1 (en) * | 2012-12-21 | 2014-06-26 | The United States of America as represented by the Secretary of Department of Health and Human Servi | Means and Methods to Diagnose Liver Toxicity using Putrescine as Biomarker |
| EP3842040B1 (en) * | 2016-01-11 | 2022-03-09 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
-
2017
- 2017-01-10 EP EP21158979.1A patent/EP3842040B1/en active Active
- 2017-01-10 EP EP17701925.4A patent/EP3402475B1/en not_active Not-in-force
- 2017-01-10 CN CN201780006292.1A patent/CN108601757A/zh active Pending
- 2017-01-10 WO PCT/IB2017/050115 patent/WO2017122120A1/en not_active Ceased
- 2017-01-10 US US16/068,626 patent/US11260060B2/en active Active
- 2017-01-10 JP JP2018555315A patent/JP7311267B2/ja active Active
- 2017-01-10 CA CA3010915A patent/CA3010915C/en active Active
- 2017-01-10 AU AU2017208123A patent/AU2017208123B2/en active Active
- 2017-01-10 RU RU2018128793A patent/RU2018128793A/ru unknown
-
2021
- 2021-12-03 JP JP2021197319A patent/JP7374163B2/ja active Active
-
2022
- 2022-01-14 US US17/576,197 patent/US12303516B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501226A5 (https=) | ||
| JP2022019973A5 (https=) | ||
| JP7374163B2 (ja) | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 | |
| JP2022519375A5 (https=) | ||
| JP2022537551A5 (https=) | ||
| JP2023533485A5 (https=) | ||
| JP2023533464A5 (https=) | ||
| JP2009501801A5 (https=) | ||
| JP2017160178A5 (https=) | ||
| BR112013020424A2 (pt) | Nitrocatecol substituído, utilizações do mesmo, combinação e composição que o compreendem | |
| JP2016530279A5 (https=) | ||
| JP2020111586A5 (https=) | ||
| JP2020500164A5 (https=) | ||
| Zhong et al. | Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review | |
| RU2018110580A (ru) | Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2018505218A5 (https=) | ||
| JP2017514858A5 (https=) | ||
| AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo | |
| JP2019500379A5 (https=) | ||
| RU2013105504A (ru) | Лекарственное средство для предотвращения и/или лечения гепатоклеточной карциномы | |
| JP2025509278A5 (https=) | ||
| JP2014509591A5 (https=) | ||
| JP2006508118A5 (https=) | ||
| JP2019524782A (ja) | Ｎ，ｎ−ビス−２−メルカプトエチルイソフタルアミドの新規用途 |